HER2 cancer vaccine (BioLife Science)

HER2癌症疫苗

Report date: 2022/07/19 16:22:54

Base Information

Drug NameHER2 cancer vaccine (BioLife Science)
Drug Alias NameHER-VaxxHer VAXXPEV-6PEV-6AIMU-131
ClassificationVaccines > Application > Therapeutic vaccine
Mechanisms of ActionImmunostimulantsReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsGastroesophageal Junction NeoplasmsStomach NeoplasmsGastrointestinal Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUkraineTaiwanThailand +[8] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesPevion Biotech Ltd
China Registration ClassN/A

Develop Information

Active CompaniesImugene Ltd
Inactive CompaniesN/A
Active IndicationsGastrointestinal NeoplasmsAdenocarcinoma
Inactive IndicationsGastroesophageal Junction NeoplasmsStomach Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A